NCNA NuCana plc

Nasdaq nucana.com


$ 3.58 $ 0.21 (6.12 %)    

Thursday, 20-Nov-2025 15:59:50 EST
QQQ $ 584.62 $ -14.20 (-2.37 %)
DIA $ 458.30 $ -3.66 (-0.79 %)
SPY $ 652.19 $ -10.10 (-1.52 %)
TLT $ 89.30 $ 0.35 (0.39 %)
GLD $ 375.00 $ -0.11 (-0.03 %)
$ 3.555
$ 3.33
$ 3.57 x 200
$ 3.59 x 14
$ 3.33 - $ 3.88
$ 2.78 - $ 330.00
151,444
na
2.52M
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nucana-announces-chinas-national-intellectual-property-administration-has-granted-a-composition-of-matter-patent-for-nuc-7738-its-novel-anti-cancer-agent

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced that the China National Intellectual Property Ad...

 reported-saturday-nucana-highlights-synergy-between-nuc-7738-and-pd-1-inhibitors-in-rcc-organoids-supporting-expansion-of-nutide701-clinical-study

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell DeathData Reinforces Mechanism of Action along with Efficacy an...

 nucana-publishes-nutide303-clinical-and-preclinical-data-on-nuc-3373-in-medrxiv-and-plos-one

NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated PatientsLatest Data ...

 nucana-cancels-all-remaining-series-a-warrants-after-raising-required-capital-eliminating-overhang-from-may-2025-offering

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Serie...

 nucana-announces-1-for-200-ads-ratio-change-effective-august-8-2025

NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced plans to change the ratio of its American Deposi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION